Isaac See

Isaac See

Auto-generated profile, based on publicly available information

Isaac See

Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, US Centers for Disease Control and Prevention , Atlanta, Georgia

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 June 2021 in JAMA
Verified
Journal Article
Open access
PDF file
ISIsaac See
Isaac See
JSJohn R. Su
John R. Su
ALAllison Lale
Allison Lale
EWEmily Jane Woo
Emily Jane Woo
AGAlice Y. Guh
Alice Y. Guh
KBKaren R. Broder
Karen R. Broder
On February 27, 2021, the US Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the single-dose Janssen/Johnson & Johnson COVID-19 (Ad26.COV2.S) vaccine, a replication-incompetent human adenovirus 26 vector vaccine.1 As of April 12, 2021, approximately 7 million doses of this vaccine had been administered nationwide.2,3

5 March 2014 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
ISIsaac See
Isaac See
YMY. Mu
Y. Mu
JCJessica Cohen
Jessica Cohen
ZBZintars G. Beldavs
Zintars G. Beldavs
LWLisa G. Winston
Lisa G. Winston
FLFernanda C. Lessa
Fernanda C. Lessa
After controlling for patient risk factors and healthcare exposures, NAP1 Clostridium difficile strain type was associated with severe disease, severe outcome, and 14-day mortality in multivariate models compared with other strain types. Background. Studies are conflicting regarding the importance of the fluoroquinolone-resistant North American pulsed-field gel electrophoresis type 1 (NAP1) strain in Clostridium difficile infection (CDI) outcome. We describe strain types causing CDI and evaluate their association with patient outcomes. Methods. CDI cases were identified from population-based surveillance. Multivariate regression models were used to evaluate the associations of strain type with severe disease (ileus, toxic megacolon, or pseudomembranous colitis within 5 days; or white blood cell count ≥15 000 cells/µL within 1 day of positive test), severe outcome (intensive care unit admission after positive test, colectomy for C. difficile infection, or death within 30 days of positive test), and death within 14 days of positive test. Results. Strain typing results were available for 2057 cases. Severe disease occurred in 363 (17.7%) cases, severe outcome in 100 (4.9%), and death within 14 days in 56 (2.7%). The most common strain types were NAP1 (28.4%), NAP4 (10.2%), and NAP11 (9.1%). In unadjusted analysis, NAP1 was associated with greater odds of severe disease than other strains. After controlling for patient risk factors, healthcare exposure, and antibiotic use, NAP1 was associated with severe disease (adjusted odds ratio [AOR], 1.74; 95% confidence interval [CI], 1.36–2.22), severe outcome (AOR, 1.66; 95% CI, 1.09–2.54), and death within 14 days (AOR, 2.12; 95% CI, 1.22–3.68). Conclusions. NAP1 was the most prevalent strain and a predictor of severe disease, severe outcome, and death. Strategies to reduce NAP1 prevalence, such as antibiotic stewardship to reduce fluoroquinolone use, might reduce CDI morbidity.

18 January 2022 in Annals of Internal Medicine
Verified
Journal Article
Closed access
ISIsaac See
Isaac See
ALAllison Lale
Allison Lale
PMPaige Marquez
Paige Marquez
MSMichael B. Streiff
Michael B. Streiff
AWAllison P. Wheeler
Allison P. Wheeler
DSDavid K. Shay
David K. Shay
Using the Vaccine Adverse Event Reporting System, the number and demographic characteristics of cases of thrombosis with thrombocytopenia syndrome occurring after receipt of COVID-19 vaccines in th... Visual Thrombosis With Thrombocytopenia Syndrome After COVID-19 Vaccination. Using the Vaccine Adverse Event Reporting System, the number and demographic characteristics of cases of thromb... Background: Thrombosis with thrombocytopenia syndrome (TTS) is a potentially life-threatening condition associated with adenoviral-vectored COVID-19 vaccination. It presents similarly to spontaneou...

1 August 2013 in Infection Control & Hospital Epidemiology
Verified
Journal Article
Closed access
PDF file
ISIsaac See
Isaac See
MIMartha Iwamoto
Martha Iwamoto
KAKathy Allen-Bridson
Kathy Allen-Bridson
THTeresa Horan
Teresa Horan
SMShelley S. Magill
Shelley S. Magill
NTNicola D. Thompson
Nicola D. Thompson
Objective.: To assess challenges to implementation of a new National Healthcare Safety Network (NHSN) surveillance definition, mucosal barrier injury laboratory-confirmed bloodstream infection (MBI-LCBI).Design.: Multicenter field test.Setting.: Selected locations of acute care hospitals participating in NHSN central line-associated bloodstream infection (CLABSI) surveillance.Methods.: Hospital staff augmented their CLABSI surveillance for 2 months to incorporate MBI-LCBI: a primary bloodstream infection due to a selected group of organisms in patients with either neutropenia or an allogeneic hematopoietic stem cell transplant with gastrointestinal graft-versus-host disease or diarrhea. Centers for Disease Control and Prevention (CDC) staff reviewed submitted data to verify whether CLABSIs met MBI-LCBI criteria and summarized the descriptive epidemiology of cases reported.Results.: Eight cancer, 2 pediatric, and 28 general acute care hospitals including 193 inpatient units (49% oncology/bone marrow transplant [BMT], 21% adult ward, 20% adult critical care, 6% pediatric, 4% step-down) conducted field testing. Among 906 positive blood cultures reviewed, 282 CLABSIs were identified. Of the 103 CLABSIs that also met MBI-LCBI criteria, 100 (97%) were reported from oncology/BMT locations. Agreement between hospital staff and CDC classification of reported CLABSIs as meeting the MBI-LCBI definition was high (90%; k= 0.82). Most MBI-LCBIs (91%) occurred in patients meeting neutropenia criteria. Some hospitals indicated that their laboratories' methods of reporting cell counts prevented application of neutropenia criteria; revised neutropenia criteria were created using data from field testing.Conclusions.: Hospital staff applied the MBI-LCBI definition accurately. Field testing informed modifications for the January 2013 implementation of MBI-LCBI in the NHSN.

2 September 2020 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
ISIsaac See
Isaac See
RGRuna H Gokhale
Runa H Gokhale
AGAndrew Geller
Andrew Geller
MLMaribeth Lovegrove
Maribeth Lovegrove
ASAsher Schranz
Asher Schranz
AFAnthony Fiore
Anthony Fiore
Background: Despite concerns about the burden of the bacterial and fungal infection syndromes related to injection drug use (IDU), robust estimates of the public health burden of these conditions are lacking. The current article reviews and compares data sources and national burden estimates for infective endocarditis (IE) and skin and soft-tissue infections related to IDU in the United States. Methods: A literature review was conducted for estimates of skin and soft-tissue infection and endocarditis disease burden with related IDU or substance use disorder terms since 2011. A range of the burden is presented, based on different methods of obtaining national projections from available data sources or published data. Results: Estimates using available data suggest the number of hospital admissions for IE related to IDU ranged from 2900 admissions in 2013 to more than 20 000 in 2017. The only source of data available to estimate the annual number of hospitalizations and emergency department visits for skin and soft-tissue infections related to IDU yielded a crude estimate of 98 000 such visits. Including people who are not hospitalized, a crude calculation suggests that 155 000–540 000 skin infections related to IDU occur annually. Discussion: These estimates carry significant limitations. However, regardless of the source or method, the burden of disease appears substantial, with estimates of thousands of episodes of IE among persons with IDU and at least 100 000 persons who inject drugs (PWID) with skin and soft-tissue infections annually in the United States. Given the importance of these types of infections, more robust and reliable estimates are needed to better quantitate the occurrence and understand the impact of interventions.

1 March 2016 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
ISIsaac See
Isaac See
AFAlison G. Freifeld
Alison G. Freifeld
SMShelley S. Magill
Shelley S. Magill
Background. Recent antimicrobial resistance data are lacking from inpatient oncology settings to guide infection prophylaxis and treatment recommendations. We describe central line–associated bloodstream infection (CLABSI) pathogens and antimicrobial resistance patterns reported from oncology locations to the Centers for Disease Control and Prevention's National Healthcare Safety Network (NHSN). Methods. CLABSI data reported to NHSN from 2009 to 2012 from adult inpatient oncology locations were compared to data from nononcology adult locations within the same hospitals. Pathogen profile, antimicrobial resistance rates, and CLABSI incidence rates per 1000 central line–days were calculated. CLABSI incidence rates were compared using Poisson regression. Results. During 2009–2012, 4654 CLABSIs were reported to NHSN from 299 adult oncology units. The most common organisms causing CLABSI in oncology locations were coagulase-negative staphylococci (16.9%), Escherichia coli (11.8%), and Enterococcus faecium (11.4%). Fluoroquinolone resistance was more common among E. coli CLABSI in oncology than nononcology locations (56.5% vs 41.5% of isolates tested; P < .0001) and increased significantly from 2009–2010 to 2011–2012 (49.5% vs 60.4%; P = .01). Furthermore, rates of CLABSI were significantly higher in oncology compared to nononcology locations for fluoroquinolone-resistant E. coli (rate ratio, 7.37; 95% confidence interval [CI], 6.20–8.76) and vancomycin-resistant E. faecium (rate ratio, 2.27, 95% CI, 2.03–2.53). However, resistance rates for some organisms, such as Klebsiella species and Pseudomonas aeruginosa, were lower in oncology than in nononcology locations. Conclusions. Antimicrobial-resistant E. coli and E. faecium have become significant pathogens in oncology. Practices for antimicrobial prophylaxis and empiric antimicrobial therapy should be regularly assessed in conjunction with contemporary antimicrobial resistance data.